Exaggerated caution or even deferment in the treatment of chronically ill mothers-to-be, for example, in the case of epilepsy, hypertension or bronchial asthma, may result in a dramatic worsening of the underlying disease and thus may threaten the further development of the fetus. On the other hand, an inadequate knowledge of the true risks of pharmacological treatment already applied in the early stages of pregnancy, leads to numerous abortions that are inappropriately indicated. As a basic rule, when planning pharmacological treatment in a pregnant woman, well tried and tested substances should be given preference over new drugs. If a pregnant woman has been exposed to an insufficiently tested substance as a result of ignorance of her pregnancy, recognized centers with appropriate data banks (www.reprotox.de) should be consulted.
CITATION STYLE
Paulus, W. (2005, April 21). Medikamente in der schwangerschaft. MMW-Fortschritte Der Medizin. https://doi.org/10.1007/978-3-662-39609-4_102
Mendeley helps you to discover research relevant for your work.